系列:实用主义试验与真实世界证据:第7篇 安全性、质量与监查
本文是八篇系列文章中的第七篇,聚焦实用主义试验中收集和报告安全性数据及监查试验实施时保持常规临床实践所面临的实践挑战。当前ICH指南要求所有严重不良事件和所有药物相关事件均须报告;作者提出基于风险的方法收集非药物相关非严重不良事件及与治疗无关的严重事件,并讨论基于风险的监查方法。
要点
- 当前ICH指南要求所有严重不良事件和所有药物相关事件均须报告
- 作者提出基于风险的方法收集非药物相关非严重不良事件及与治疗无关的严重事件
- 作者讨论基于风险的监查方法,强调实用主义试验与传统临床试验的风险平衡差异
核心结论
- 当前ICH指南要求所有严重不良事件和所有药物相关事件均须报告
- 作者提出基于风险的方法收集非药物相关非严重不良事件及与治疗无关的严重事件,依据药物/类别在目标人群中的风险特征
- 作者讨论基于风险的监查方法,强调实用主义试验与传统临床试验风险平衡的差异及维护常规诊疗需仔细考虑风险的缓解与管理
研究设计与样本
- 本文为系列文章中的第七篇,描述设计选择对实用主义试验实际实施的影响
- 本文聚焦收集和报告安全性数据及监查试验实施时保持常规临床实践的实践挑战
关键数值与推荐
- 当前ICH指南要求所有严重不良事件和所有药物相关事件均须报告
- 作者提出基于风险的方法收集非药物相关非严重不良事件及与治疗无关的严重事件,依据药物/类别在目标人群中的风险特征
临床怎么用
- 作者提出基于风险的方法收集非药物相关非严重不良事件及与治疗无关的严重事件,依据药物/类别在目标人群中的风险特征
- 作者讨论基于风险的监查方法,强调实用主义试验与传统临床试验风险平衡的差异及维护常规诊疗需仔细考虑风险的缓解与管理
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pragmatic trials offer the opportunity to obtain real-life data on the relative effectiveness and safety of a treatment before or after market authorization. This is the penultimate paper in a series of eight, describing the impact of design choices on the practical implementation of pragmatic trials. STUDY DESIGN AND SETTING: This paper focuses on the practical challenges of collecting and reporting safety data and of monitoring trial conduct while maintaining routine clinical care practice. CONCLUSION: Current ICH guidance recommends that all serious adverse events and all drug-related events must be reported in an interventional trial. In line with current guidance, we propose a risk-based approach to the collection of non-drug-related non-serious adverse events and even serious events not related to treatment based on the risk profile of the medicine/class in the patient population of interest. Different options available to support the collection and reporting of safety data while minimizing study-related follow-up visits are discussed. A risk-based approach to monitoring trial conduct is also discussed, highlighting the difference in the balance of risks likely to occur in a pragmatic trial compared to traditional clinical trials and the careful consideration that must be given to the mitigation and management of these risks to maintain routine care.
引用
- Irving E, van den Bor R, Welsing P, et al. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring. J Clin Epidemiol. 2017. PMID: 28502812. doi:10.1016/j.jclinepi.2017.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。